A Big Check, a Solar Detour, and a Biotech Story That Knows It Looks Good

One biotech name just got a giant wink from smart money, one solar player is choosing caution over bravado, and one high-flyer still has a strong story but no longer comes with bargain-bin pricing. We’ll show you where a starter buy may work, where to wait for the dust to settle, and where better timing matters more than excitement.

Operation Epic Fury showed the scale and speed at which modern warfare can mobilize - with the U.S. striking more than 2,000 Iranian military targets in just 96 hours.

Stealth bombers. Fighter jets. Cruise missiles. Autonomous drones.

Every one of those systems relies on titanium.

Today, the U.S. imports more than 95% of its supply, while China's share of global titanium metals has surged to over 75%.

As defense production ramps up and geopolitical tensions rise, that dependence is becoming a serious vulnerability.

Titanium just became a strategic chokepoint.

According to Project Blue, the West is heading toward a titanium supply crunch, with aerospace and defense expected to feel the pressure first.

That's the backdrop for what this explorer just found in North America.

Their Radar Project has emerged as a potential Western rival to China's largest titanium mine.

All 31 holes drilled on the property to-date report significant and consistent titanium grades across extensive intercepts.

With Western supply chains under pressure, discoveries like Radar could become increasingly strategic.

Get the Full Breakdown

Futures are bouncing as oil cools off and traders grab onto fresh hopes that the Iran mess may finally be inching toward an exit ramp. Powell helped calm things down a bit too, so this morning feels like one of those fragile relief rallies where everyone is smiling, but still checking the news every five minutes.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Earnings (Premarket):
• McCormick & Company, Incorporated [MKC]
• McCormick & Company, Incorporated [MKC.V]
• TD SYNNEX Corporation [SNX]
• FactSet Research Systems Inc. [FDS]
• Chagee Holdings Limited [CHA]
• T1 Energy Inc. [TE]

Earnings (Aftermarket):
• Nike, Inc. [NKE]
• PVH Corp. [PVH]
• RH [RH]
• nCino, Inc. [NCNO]

Economic Reports:
• S&P Case-Shiller home price index, 20 cities (Jan): 9:00 am
• Chicago Business Barometer, PMI (March): 9:45 am
• Job openings (Feb): 10:00 am
• Consumer confidence (March): 10:00 am

Fed Speakers:
• Chicago Fed President Austan Goolsbee speaks: 12:00 pm
• Fed governor Michael Barr speaks: 3:00 pm
• Fed Vice Chair for Supervision Michelle Bowman speaks: 5:10 pm

Wave Life Sciences Ltd [WVE] is getting a boost because RA Capital did not just send flowers, it backed up the truck. A big open-market buy from a biotech-focused heavyweight tends to get attention fast, especially in a name that has already had a rough ride. When a smart money shop adds that aggressively, the market usually reads it as more than casual window shopping.

That does not mean the company suddenly became simple. This is still biotech, which means the science has to keep earning the optimism, and the stock can still behave like it had too much coffee. But a buyer like this changes the mood.

It tells traders and longer-term investors that somebody with real homework believes the current price may be too cheap for the platform and pipeline. That alone can pull fresh eyeballs back to the chart.

The catch is that institutional buying is a clue, not a guarantee. You still need the company to execute, and biotech names can stay moody even when the smart crowd is leaning in. So this is encouraging, but not magic.

My Take For You: Fine for a small speculative starter if you like following smart-money footprints, but do not treat one big buy like a free lunch.

My Verdict: Strong signal, better sentiment, and worth watching closely. Interesting for a nibble, but still biotech rules apply.

First Solar Inc [FSLR] is bouncing even after weaker guidance, which sounds weird until you remember the market sometimes likes a company more when it chooses caution instead of pretending everything is fine.

Management is dialing back some Southeast Asia production while it figures out the tariff mess, and that looks like a short-term headache meant to avoid a bigger one later. It is not flashy, but it is practical.

That matters because this stock has already been through enough turbulence to make investors a little numb. The market knows tariffs are real, supply chains are messy, and clean energy names have spent plenty of time getting smacked around by policy drama.

So the story here is less wow, guidance got weaker, and more okay, they are trying not to drive into a pothole at full speed. The U.S.-heavy manufacturing angle still gives this company a cleaner story than many peers, even if the near-term numbers get a little uglier.

The risk is obvious. If tariff costs keep spreading and output stays constrained for too long, patience will wear thin. This is not broken, but it is not smooth either.

My Take For You: Fine to watch for a dip buy, but let the tariff fog clear a bit before getting aggressive.

My Verdict: Still one of the cleaner solar stories, just with more near-term bumps than investors wanted.

Earlier this year, a U.S. defense-linked consortium issued a request for proposals focused on nickel supply and processing capacity.

Now, one micro-cap subsea mining company has submitted a formal bid, putting itself into a supply chain conversation that’s growing increasingly urgent.

The backdrop: a push to secure domestic or allied sources of strategic materials used in advanced manufacturing and military systems.

It’s still early-stage, but this filing moves the story beyond a concept.

[View the Report]

*This communication is a paid advertisement published by Capital Gain Media Incorporated and does not constitute a recommendation, offer, or solicitation to buy or sell securities. Capital Gain Media Incorporated has been compensated by Deep Sea Minerals Corp. with four hundred thousand dollars (USD 400,000) plus applicable taxes for an ongoing marketing campaign, which includes the publication of this communication. This compensation constitutes a significant conflict of interest with respect to our impartiality. This communication is for entertainment and informational purposes only. Never invest solely on the basis of our communications. The owner of Capital Gain Media may buy or sell securities of this issuer for its own profit. Resource exploration and development is highly speculative and involves significant inherent risks. There is no guarantee that Deep Sea Minerals Corp will generate a return on investment. All forward-looking statements involve risks and uncertainties. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult a licensed financial advisor before making any investment decisions. For complete risk factors, refer to Deep Sea Minerals Corp.'s continuous disclosure documents available at www.sedarplus.ca.

Roivant Sciences Ltd [ROIV] is slipping a bit, but the bigger picture is that this stock has already had a huge run, and now the market is asking the classic question: great story, but how much of it is already in the price.

The latest analyst note stays bullish because the drug data still looks strong, doctors sound enthusiastic, and the sales potential being tossed around is big enough to make biotech investors lean in. That is the good part.

The harder part is that once a stock has doubled and then some, it stops getting rewarded just for having a nice future. It has to keep proving that the future is getting closer, cleaner, and bigger.

Roivant still has that potential, and the drug story sounds strong enough to keep people interested, but a lot of the easy excitement has already shown up on the chart. That can make even good news feel a little less magical in the short term.

So this looks more like a digestion day than a broken thesis. The company still has meaningful catalysts ahead, but the stock is no longer sneaking around unnoticed.

My Take For You: Better to wait for weakness than chase it after such a big run. Start small if you want exposure.

My Verdict: Strong story, real upside, but the stock needs fresh fuel now that expectations are no longer modest.

KB Financial Group Inc [KB] is slipping a bit even after all the nice dividend talk, which is a good reminder that bigger payouts do not always mean instant fireworks.

The company is clearly trying to make itself more attractive to income investors, and a 31.7% dividend jump is nothing to sneeze at, but after a huge run, some folks may just be taking chips off the table.

Hycroft Mining Holding Corporation [HYMC] looks like it is catching a lift because precious metals are perking up again, and this stock usually does not need a second invitation when gold and silver start acting frisky.

When the shiny stuff moves higher, miners like this tend to wake up fast, even if the underlying business still comes with plenty of sharp edges.

Huntsman Corporation [HUN] is getting a little boost from the Hungary expansion story, which helps paint the company as less sleepy than the stock usually feels.

The idea is simple enough: trim weaker pieces, build up the better ones, and hope the specialty chemicals mix starts looking more profitable down the road. Nice plan, still needs proof.

As conflict headlines dominate the news, a bigger opportunity may be forming behind the scenes.

SpaceX has become deeply embedded in U.S. defense infrastructure across all military branches.

But its next move could impact investors far more than geopolitics.

There’s increasing talk that Elon Musk may eventually take the company public.

If it happens, it could become one of the most significant IPOs in market history.

Some investors are already looking for ways to position ahead of that possibility.

See How They’re Doing It Here

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.